Triptorelin Reconstitution Calculator

Yes. Triptorelin is an established prescription GnRH agonist with approved depot formulations used in multiple indications, including central precocious puberty and prostate cancer; the corpus also notes an FDA-approved spray-dried depot product history and multiple phase 3/real-world clinical uses. Evidence quality for approval status in this corpus is indirect rather than regulatory-label primary documentation, but the clinical use is well established.

Both work. In a randomized trial using 100 mcg triptorelin for CPP testing, IM and SC administration produced similar LH response timing and similar diagnostic yield, with about 97% of diagnoses captured within 30 minutes in both groups. For chronic treatment, depot triptorelin is commonly given IM in 3.75 mg monthly, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks formulations in pediatric CPP cohorts.

It depends on the use case. For CPP diagnosis, published protocols used 100 mcg SC or IM with serial LH sampling up to 120 minutes; CPP peak LH often appears around 30–60 minutes, though with SC triptorelin some patients peak later and 120-minute sampling improves sensitivity. For CPP treatment, common regimens in the corpus are 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, and 22.5 mg every 24 weeks, all showing effective suppression in most children. In practice, some clinicians individualize interval length to 3, 4, or 5 weeks based on suppression and growth goals.

Medium- to longer-term use is common when clinically indicated. Pediatric cohorts in CPP show maintained LH/estradiol suppression through 24–36 months with 6-month formulations, along with slowed bone-age advancement and improved predicted adult height. A UK multicenter cohort found 24-weekly Decapeptyl SR performed comparably to 12-weekly treatment, supporting prolonged use when monitoring confirms continued suppression.

Usually not for standard depot CPP dosing. Population PK modeling of a 3.75-mg triptorelin microsphere formulation found no significant effect of weight, age, albumin, liver markers, bilirubin, creatinine, or creatinine clearance on PK model covariates, and supported a fixed-dose approach despite somewhat higher exposure in lighter children. Simulations showed roughly 1.7-fold higher exposure in 20–30 kg versus 40–50 kg children, but this was judged not clinically meaningful because of a plateau pharmacodynamic effect and wide therapeutic range.

For diagnostic stimulation, triptorelin performs similarly to classic GnRH/gonadorelin testing and is a practical substitute where IV GnRH is unavailable. For treatment, evidence in the corpus supports monthly, 3-month, and 6-month triptorelin depot options as effective for HPG-axis suppression, pubertal stabilization, and height preservation. Choice versus leuprolide or histrelin is usually driven by formulation interval, local availability, cost, and clinician familiarity (practitioner consensus).

Expected effects stem from sex-steroid suppression: hot flashes, mood changes, headache, injection-site reactions, and reduced bone accrual over time are standard class concerns (practitioner consensus). In FAERS pharmacovigilance data across GnRH agonists, depression and suicide/self-injury signals were reported, with earlier onset in females and younger patients; this is hypothesis-generating rather than proof of causality, but it supports monitoring mood symptoms, especially in adolescents and oncology patients. Injection-site granuloma or sterile abscess can occur with GnRH agonists in rare cases based on case-level literature in the corpus.

Not as a routine pregnancy medication. In fertility practice, triptorelin is used strategically for pituitary control or ovulation trigger before conception steps, not as ongoing support during pregnancy; IVF literature in the corpus uses single trigger doses such as 0.2–0.3 mg around final oocyte maturation, then stops. If pregnancy occurs unexpectedly during active long-acting suppression, management is case-specific and should be reviewed with the treating clinician immediately (practitioner consensus).

Yes. In CPP treatment, monitoring typically includes growth velocity, Tanner staging, bone age, and hormone suppression markers such as LH/FSH and estradiol/testosterone. If suppression is inadequate, some protocols shorten the dosing interval; if suppression is adequate, intervals may be extended in selected patients. For diagnostic testing, one well-timed LH sample can sometimes be sufficient, but 120-minute sampling is the safer standard when using triptorelin because delayed peaks are not rare.